CSL Limited

Quick facts

Phase 3 pipeline

• Ig NextGen 10% · Immunology
  Ig NextGen 10% is an intravenous immunoglobulin (IVIG) product that provides passive immunity by delivering pooled human antibodies to modulate immune function and replace deficient immunoglobulins.
• IgNextGen 10% · Immunology; Hematology
  IgNextGen 10% is an intravenous immunoglobulin (IVIG) product that provides passive immunity by delivering pooled human antibodies to modulate immune function and replace deficient immunoglobulins.
• IgNextGen 16% · Immunology
  IgNextGen 16% is an intravenous immunoglobulin (IVIG) product that provides passive immunization by delivering pooled human antibodies to modulate immune function and replace deficient immunoglobulins.
• IntragamP · Immunology
  IntragamP is an intravenous immunoglobulin (IVIG) preparation that provides passive immunity by delivering pooled human antibodies to modulate immune responses.

Phase 2 pipeline

• rHDL

Phase 1 pipeline

• CSL360
• CSL362

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• CSL Limited portfolio CI brief
• CSL Limited pipeline updates RSS